-

Two New Members Elected to Owens & Minor Board of Directors

RICHMOND, Va.--(BUSINESS WIRE)--Owens & Minor, Inc. (NYSE: OMI), a leading global healthcare solutions company, today announced the election of Aster Angagaw and Stephen W. Klemash to its Board of Directors.

These additions build on Owens & Minor’s enduring commitment to business excellence and serving our customers.

“I’m thrilled to welcome Aster and Steve to the Board,” said Mark A. Beck, Chairman of the Board. “Their range of perspectives will provide essential insight in supporting Owens & Minor’s continued growth and success in an ever-changing healthcare industry landscape.”

Aster Angagaw, 57, has a strong background in transformational growth with extensive experience leading diverse global teams. Most recently, she served as President, ServiceMaster Brands, until its acquisition in October 2020. Prior to that, she spent 18 years at Sodexo, where she held a variety of leadership positions, including Senior Vice President, Global Head of Sales and Business Development, Healthcare, and Group Vice President, Global Transformation, before being named Chief Executive Officer, Healthcare North America division in 2016.

Stephen W. Klemash, 60, brings considerable expertise in finance, corporate governance and board effectiveness. Steve is currently the Lead Partner with the Ernst & Young LLP (EY) Americas Center for Board Matters with plans to retire from the firm in July 2021. He has been a Partner with EY since 1997, where he held multiple Managing Partner and leadership positions in his 35-year career.

“Aster and Steve each have unique skillsets that will help inform Owens & Minor’s standing as an industry innovator and a valued partner to our customers,” said Owens & Minor President and CEO Edward A. Pesicka. “The needs of our customers are constantly evolving, and I’m confident our Board will help ensure that we’re positioned to deliver on our Mission of Empowering Our Customers to Advance Healthcare now and in the future.”

Ms. Angagaw and Mr. Klemash have been elected to the Board as part of a multi-year succession planning process. Along with all current directors of the Company other than Robert Sledd and Eddie Moore, Jr., Ms. Angagaw and Mr. Klemash will be nominated for re-election at the Company’s upcoming 2021 annual meeting of shareholders. Mr. Sledd previously announced his retirement from the Board effective as of the 2021 annual meeting of shareholders, and Mr. Moore will retire from the Board on the same date in accordance with the Company’s director retirement policy.

About Owens & Minor

Owens & Minor, Inc. (NYSE: OMI) is a global healthcare solutions company that incorporates product manufacturing, distribution support and innovative technology services to deliver significant and sustained value across the breadth of the industry – from acute care to patients in their home. Aligned to its Mission of Empowering Our Customers to Advance Healthcare™, more than 15,000 global teammates serve over 4,000 healthcare industry customers. A vertically-integrated, predominantly Americas-based footprint enables Owens & Minor to reliably supply its self-manufactured surgical and PPE products. This seamless value chain integrates with a portfolio of products representing 1,200 branded suppliers. Operating continuously since 1882 from its headquarters in Richmond, Virginia, Owens & Minor has grown into a FORTUNE 500 company with operations located across North America, Asia, Europe and Latin America. For more information about Owens & Minor, visit owens-minor.com, follow @Owens_Minor on Twitter and connect on LinkedIn at www.linkedin.com/company/owens-&-minor.

Contacts

Owens & Minor, Inc.

NYSE:ACH
Details
Headquarters: Richmond, VA
CEO: Edward Pesicka
Employees: 6000
Organization: PUB

Release Summary
Press release of new board members, for distro after Earnings release, before 7am
Release Versions

Contacts

More News From Owens & Minor, Inc.

Accendra Health Announces Extension of $150 Million Receivables Sale Program To 2029

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) today announced that it executed an amendment to its Receivables Purchase Agreement (the “Receivables Sale Program”) on October 29, 2026. The amendment, among other things, extends the Scheduled Termination Date of the facility to October 2029, and the $150 million size of the Receivables Sale Program is unchanged. “We are pleased to have worked with our banking partner to extend the Receivables Sale Program until...

Accendra Health Receives Continued Listing Standard Notice from NYSE Regarding Market Capitalization and Stockholders’ Equity; Intends to Submit Business Plan and Return to Compliance with NYSE Listing Standard​

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the Company) today announced that on October 27, 2026, it received a notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) notifying the Company that it is not in compliance with Section 802.01B of the NYSE’s continued listing standards that the Company have an average market capitalization of not less than $50.0 million over a consecutive 30 trading-day period and stockholders’ equity of not less than $50.0 millio...

Accendra Health Announces Third Quarter 2026 Earnings Release Date and Conference Call

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) plans to release financial results for the third quarter of 2026 on Thursday, November 5, 2026, after trading ends on the New York Stock Exchange.The Company will host a conference call for investors and analysts at 5:00 p.m. EST on the same day. Participants may access the call via the toll-free dial-in number at 1-833-461-5787, or the toll dial-in number at 1-585-542-9983. The conference ID access code is 829 856...
Back to Newsroom